Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byAstraZeneca
Price$1.15B
Date6/2013

General Information

Websitepearltherapeutics...
CategoryBioTech
Phone650-305-2600
Employees
Founded2006
DescriptionRespiratory Disease research

Offices

Corporate Headquarters
200 Saginaw Drive
Redwood City, CA, 94063
USA

People

President & CEO

Funding

Tags

Pearl Therapeutics

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease.

Pearl’s current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.

Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Recent Milestones

Videos

Screenshots

Pearl Therapeutics screenshot
Above: Pearl Therapeutics
Uploaded: 6/26/09

Sources

  1. AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 billion (reuters.com) [edit]
  2. Pearl Therapeutics ups its first round funding (venturebeat.com) [edit]
  3. Pearl Therapeutics, Inc.: Series C $15M (onbiovc.com) [edit]
  4. Pearl lands $69M Series C for mid-stage COPD program (fiercebiotech.com) [edit]
  5. VC funding: Q4 2012 [edit]
  6. Pearl Therapeutics Raises $65M in Series D Financing (finsmes.com) [edit]
  7. VC Funding: Q2 2013 source [edit]
Edit This Page
Last Edited 4/9/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy